Lukas Hawinkels

Dr. Lukas Hawinkels

Department of Gastroenterology-Hepatology, Leiden University Medical Center - LUMC, Leiden, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2015 in Nature
Verified
Journal Article
Open access
PDF file
SCSeth B. Coffelt
Seth B. Coffelt
KKKelly Kersten
Kelly Kersten
CDChris W. Doornebal
Chris W. Doornebal
JWJorieke Weiden
Jorieke Weiden
KVKim Vrijland
Kim Vrijland
KVKarin E de Visser
Karin E de Visser
Tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis. That tumorigenesis can be closely linked to an inflammatory microenvironment has been well established. In a new study, Karin de Visser and colleagues estimate the more systemic inflammatory effects observed in a mouse model of breast cancer. They find that interleukin (IL)-1β expression in tumours elicits IL-17 expression in γδ T cells at a local level, which through granulocyte colony-stimulating factor production promotes systemic accumulation of neutrophils in multiple organs. Interfering with this cascade of events, for example at the level of neutrophil activation, reduces lung and lymph node metastases in this breast cancer model. These findings illustrate the perhaps wider than anticipated systemic effects elicited by localized tumours, at the same time offering multiple points of potential therapeutic interference. Metastatic disease remains the primary cause of death for patients with breast cancer. The different steps of the metastatic cascade rely on reciprocal interactions between cancer cells and their microenvironment. Within this local microenvironment and in distant organs, immune cells and their mediators are known to facilitate metastasis formation1,2. However, the precise contribution of tumour-induced systemic inflammation to metastasis and the mechanisms regulating systemic inflammation are poorly understood. Here we show that tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis. We mechanistically demonstrate that interleukin (IL)-1β elicits IL-17 expression from gamma delta (γδ) T cells, resulting in systemic, granulocyte colony-stimulating factor (G-CSF)-dependent expansion and polarization of neutrophils in mice bearing mammary tumours. Tumour-induced neutrophils acquire the ability to suppress cytotoxic T lymphocytes carrying the CD8 antigen, which limit the establishment of metastases. Neutralization of IL-17 or G-CSF and absence of γδ T cells prevents neutrophil accumulation and downregulates the T-cell-suppressive phenotype of neutrophils. Moreover, the absence of γδ T cells or neutrophils profoundly reduces pulmonary and lymph node metastases without influencing primary tumour progression. Our data indicate that targeting this novel cancer-cell-initiated domino effect within the immune system—the γδ T cell/IL-17/neutrophil axis—represents a new strategy to inhibit metastatic disease.

6 December 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
MFMarieke F. Fransen
Marieke F. Fransen
MSMark Schoonderwoerd
Mark Schoonderwoerd
PKPhilipp Knopf
Philipp Knopf
MCMarcel G.M. Camps
Marcel G.M. Camps
Lukas HawinkelsLukas Hawinkels
Lukas Hawinkels
FOFerry Ossendorp
Ferry Ossendorp
PD-1/PD-L1 checkpoint therapy for cancer is commonly considered to act by reactivating T cells in the tumor microenvironment. Here, we present data from 2 mouse tumor models demonstrating an essential involvement of tumor-draining lymph nodes in PD-1 and PD-L1 therapeutic efficacy. Immune activation induced by checkpoint treatment was predominantly observed in the tumor-draining, but not nondraining, lymph nodes and was reflected in local accumulation of CD8 + T cells. Surgical resection of these lymph nodes, but not contralateral lymph nodes, abolished therapy-induced tumor regressions and was associated with decreased immune infiltrate in the tumor microenvironment. Moreover, inhibitor FTY720, which locks lymphocytes in lymph organs, also abrogated checkpoint therapy, suggesting that the tumor-draining lymph nodes function as sites of T cell invigoration required for checkpoint blockade therapy. Now that PD-1/PD-L1 checkpoint treatment is applied in earlier clinical stages of cancer, our preclinical data advocate for enrolling patients with their tumor-draining lymph nodes still in place, to optimally engage the antitumor immune response and thereby enhance clinical benefit.

3 December 2012 in Oncogene
Verified
Journal Article
Closed access
PDF file
Lukas HawinkelsLukas Hawinkels
Lukas Hawinkels
MPM Paauwe
M Paauwe
HVH W Verspaget
H W Verspaget
EWEliza Wiercinska
Eliza Wiercinska
JZJ M van der Zon
J M van der Zon
Cornelis SierCornelis Sier
Cornelis Sier

12 May 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
Lukas HawinkelsLukas Hawinkels
Lukas Hawinkels
PKPatricia Kuiper
Patricia Kuiper
EWEliza Wiercinska
Eliza Wiercinska
HVHein W. Verspaget
Hein W. Verspaget
ZLZhen Liu
Zhen Liu
PDPeter Ten Dijke
Peter Ten Dijke
Endoglin is a transforming growth factor-β coreceptor with a crucial role in angiogenesis. A soluble form of endoglin is present in the circulation, but the role of soluble endoglin (sEndoglin) is poorly understood. In addition, the endoglin shedding mechanism is not known. Therefore, we examined the role of sEndoglin in tumor angiogenesis and the mechanism by which the extracellular domain of endoglin is released from the membrane.In colorectal cancer specimens, we observed high endothelial endoglin protein expression, accompanied with slightly lower sEndoglin levels in the circulation, compared with healthy controls. In vitro analysis using endothelial sprouting assays revealed that sEndoglin reduced spontaneous and vascular endothelial growth factor–induced endothelial sprouting. Human umbilical vascular endothelial cells were found to secrete high levels of sEndoglin. Endoglin shedding was inhibited by matrix metalloproteinase (MMP) inhibitors and MMP-14 short hairpin RNA, indicating MMP-14 as the major endoglin shedding protease. Coexpression of endoglin and membrane-bound MMP-14 led to a strong increase in sEndoglin levels. Endoglin shedding required a direct interaction between endoglin and membrane-localized MMP-14. Using cleavage site mutants, we determined that MMP-14 cleaved endoglin at a site in close proximity to the transmembrane domain. Taken together, this study shows that MMP-14 mediates endoglin shedding, which may regulate the angiogenic potential of endothelial cells in the (colorectal) tumor microenvironment. Cancer Res; 70(10); 4141–50. ©2010 AACR.

1 September 2008 in European Journal of Cancer
Verified
Journal Article
Closed access
Lukas HawinkelsLukas Hawinkels
Lukas Hawinkels
KZKim Zuidwijk
Kim Zuidwijk
HVHein W. Verspaget
Hein W. Verspaget
EJEveline S.M. de Jonge-Muller
Eveline S.M. de Jonge-Muller
WDWim van Duijn
Wim van Duijn
Cornelis SierCornelis Sier
Cornelis Sier

3 March 2014 in Nature Communications
Verified
Journal Article
Closed access
PDF file
FZFangFang Zhou
FangFang Zhou
YDYvette Drabsch
Yvette Drabsch
TDTim J. A. Dekker
Tim J. A. Dekker
AVAmaya Garcia de Vinuesa
Amaya Garcia de Vinuesa
YLYihao Li
Yihao Li
PDPeter Ten Dijke
Peter Ten Dijke